[{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Techdow USA","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Fosaprepitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Techdow USA","highestDevelopmentStatusID":"15","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Techdow USA"},{"orgOrder":0,"company":"Avenacy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fosaprepitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avenacy \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avenacy \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fosaprepitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fosaprepitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Fosaprepitant

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Focinvez (fosaprepitant) is the first ready-to-use, single-dose injection to prevent acute and delayed nausea & vomiting from emetogenic cancer chemotherapy in adults and children 6 months and older.

                          Product Name : Focinvez

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 07, 2024

                          Lead Product(s) : Fosaprepitant

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Emend-Generic (fosaprepitant) is an NK1 receptor antagonist for preventing nausea and vomiting in adults and pediatric patients aged 6 months and older during chemotherapy.

                          Product Name : Emend-Generic

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 18, 2024

                          Lead Product(s) : Fosaprepitant

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Chia Tai Tianqing Pharmaceutical Group

                          Country arrow
                          iPHEX India
                          Not Confirmed

                          Chia Tai Tianqing Pharmaceutical Group

                          Country arrow
                          iPHEX India
                          Not Confirmed

                          Details : Under the agreement, CTTQ will manufacture Fosaprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist, for Injection, the therapeutic generic equivalent of Emend, and will be sold under the Techdow USA Label.

                          Product Name : Emend-Generic

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          August 22, 2023

                          Lead Product(s) : Fosaprepitant

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved FDF

                          Sponsor : Techdow USA

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Fosaprepitant for Injection, 150 mg Single-Dose Vial, is the generic equivalent of Emend® for Injection, 150 mg Single-Dose Vial, of Merck indicated for adults in combination with other antiemetic agents.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 28, 2020

                          Lead Product(s) : Fosaprepitant

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 13, 2019

                          Lead Product(s) : Fosaprepitant

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 11, 2015

                          Lead Product(s) : Fosaprepitant

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Ajeet Gajra

                          Country arrow
                          iPHEX India
                          Not Confirmed

                          Ajeet Gajra

                          Country arrow
                          iPHEX India
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 03, 2015

                          Lead Product(s) : Fosaprepitant

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Merck & Co

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          St. Louis University

                          Country arrow
                          iPHEX India
                          Not Confirmed

                          St. Louis University

                          Country arrow
                          iPHEX India
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 10, 2013

                          Lead Product(s) : Fosaprepitant

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase II

                          Sponsor : Merck & Co

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Lawrence Einhorn

                          Country arrow
                          iPHEX India
                          Not Confirmed

                          Lawrence Einhorn

                          Country arrow
                          iPHEX India
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 29, 2012

                          Lead Product(s) : Fosaprepitant

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase II

                          Sponsor : Hoosier Cancer Research Network | Merck & Co

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 02, 2012

                          Lead Product(s) : Fosaprepitant

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank